The Panel will address the increasing legal issues faced
by life sciences companies, risk management and mitigation strategies, as well
investment in biotechnology companies. Issues to be covered will include
valuations issues, manufacturing/safety/quality control issues, sales and
marketing issues (e.g., off-label), clinical trial issues, payments to
healthcare professionals (Sunshine Act) issues, insider trading, and other
issues that impact investment, operations, and expansion strategies. These
will be approached from a business/transactional perspective.
Reception to directly follow program.